Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients

Authors: A Langerød, TI Andersen, I Bukholm, A-L Børresen Dale

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

Case-control studies have reported association between polymorphisms in the TP53 gene and breast cancer [1]. We have examined whether certain alleles or haplotypes show association with loss of heterozygosity (LOH) or mutations in TP53. Our hypothesis is that certain alleles may predispose for breast cancer through a mechanism promoting LOH or mutations. 452 breast cancer patients were genotyped for three intergenic polymorphisms [2,3,4] and one polymorphism located downstream of the gene [5]. The SNPs (Single Nucleotide Polymorphisms) in exon 4 and intron 6 were analysed using the restriction enzymes BstUI and MspI respectively, while the 16 bp insertion in intron 3 and the VNTR downstream of the gene were examined using capillary electrophoresis. LOH and mutation analyses have previously been performed in samples from the same cohort. In conclusion, we were not able to demonstrate any statistical significance implying that any of these polymorphisms were associated with increased risk of LOH or mutation of the TP53 gene. …
Metadata
Title
Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
Authors
A Langerød
TI Andersen
I Bukholm
A-L Børresen Dale
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr110

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine